Biogen announces licensing of Denali’s ATV to target Amyloid Beta
pharmafile | April 13, 2023 | News story | Research and Development |
Biogen and Denali Therapeutics have announced that Biogen has exercised its option to license Denali’s Antibody Transport Vehicle: Amyloid beta programme (ATV:Aβ) which targets Amyloid beta. Accumulation of this plaque is a common feature of Alzheimer’s disease (AD).
Biogen plans to use the ATV platform to cross the blood-brain barrier (BBB), as ATV:Aβ is designed to increase brain exposure and target engagement of antibody therapeutics that are directed against Aβ, potentially allowing for improved plaque clearance and reduced amyloid-related imaging abnormalities (ARIA).
Joseph Lewcock, PhD, CSO of Denali, commented: “Recent progress with Aβ-directed therapeutic antibodies enables new treatment options for people living with AD, and clinical trial data has demonstrated that clearance of aggregated Aβ is associated with benefit for patients. Our ATV:Aβ programme is designed to safely increase exposure of the therapeutic antibody in the brain and potentially lead to improved efficacy and/or safety. We are pleased with Biogen’s decision to license ATV:Aβ and we are hopeful this will foster the development of next-generation anti-Aβ therapeutics.”
Dominic Walsh, head of the Neurodegenerative Research Unit at Biogen, added: “This decision is an important next step of our collaboration with Denali on ATV:Aβ that aims to advance the next generation of Aβ immunotherapies for the treatment of Alzheimer’s disease. This programme reinforces the importance of targeting Aβ and our commitment to Alzheimer’s disease.”